Literature DB >> 21865360

MicroRNAs in thyroid cancer.

Albert de la Chapelle1, Krystian Jazdzewski.   

Abstract

CONTEXT: Traditionally, factors predisposing to diseases are either genetic ("nature") or environmental, also known as lifestyle-related ("nurture"). Papillary thyroid cancer is an example of a disease where the respective roles of these factors are surprisingly unclear. EVIDENCE ACQUISITION: Original articles and reviews summarizing our current understanding of the role of microRNA in thyroid tumorigenesis are reviewed and evaluated.
CONCLUSION: The genetic predisposition to papillary thyroid cancer appears to consist of a variety of gene mutations that are mostly either of low penetrance and common or of high penetrance but rare. Moreover, they likely interact with each other and with environmental factors. The culpable genes may not be of the traditional, protein-coding type. A limited number of noncoding candidate genes have indeed been described, and we propose here that the failure to find mutations in traditional protein-coding genes is not coincidental. Instead, a more likely hypothesis is that changes in the expression of multiple regulatory RNA genes, e.g. microRNAs, may be a major mechanism. Our review of the literature strongly supports this notion in that a polymorphism in one microRNAs (miR-146a) predisposes to thyroid carcinoma, whereas numerous other microRNAs are involved in signaling (mainly PTEN/PI3K/AKT and T3/THRB) that is central to thyroid carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21865360      PMCID: PMC3410255          DOI: 10.1210/jc.2011-1004

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  106 in total

1.  Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.

Authors:  Milena S Nicoloso; Hao Sun; Riccardo Spizzo; Hyunsoo Kim; Priyankara Wickramasinghe; Masayoshi Shimizu; Sylwia E Wojcik; Jana Ferdin; Tanja Kunej; Lianchun Xiao; Siranoush Manoukian; Giorgio Secreto; Fernando Ravagnani; Xuemei Wang; Paolo Radice; Carlo M Croce; Ramana V Davuluri; George A Calin
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  Reprogramming of miRNA networks in cancer and leukemia.

Authors:  Stefano Volinia; Marco Galasso; Stefan Costinean; Luca Tagliavini; Giacomo Gamberoni; Alessandra Drusco; Jlenia Marchesini; Nicoletta Mascellani; Maria Elena Sana; Ramzey Abu Jarour; Caroline Desponts; Michael Teitell; Raffaele Baffa; Rami Aqeilan; Marilena V Iorio; Cristian Taccioli; Ramiro Garzon; Gianpiero Di Leva; Muller Fabbri; Marco Catozzi; Maurizio Previati; Stefan Ambs; Tiziana Palumbo; Michela Garofalo; Angelo Veronese; Arianna Bottoni; Pierluigi Gasparini; Curtis C Harris; Rosa Visone; Yuri Pekarsky; Albert de la Chapelle; Mark Bloomston; Mary Dillhoff; Laura Z Rassenti; Thomas J Kipps; Kay Huebner; Flavia Pichiorri; Dido Lenze; Stefano Cairo; Marie-Annick Buendia; Pascal Pineau; Anne Dejean; Nicola Zanesi; Simona Rossi; George A Calin; Chang-Gong Liu; Jeff Palatini; Massimo Negrini; Andrea Vecchione; Anne Rosenberg; Carlo M Croce
Journal:  Genome Res       Date:  2010-05       Impact factor: 9.043

3.  Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486.

Authors:  Eric M Small; Jason R O'Rourke; Viviana Moresi; Lillian B Sutherland; John McAnally; Robert D Gerard; James A Richardson; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-08       Impact factor: 11.205

4.  miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.

Authors:  Chen-Kai Chou; Rong-Fu Chen; Fong-Fu Chou; Hsueh-Wen Chang; Yi-Ju Chen; Ya-Fang Lee; Kuender D Yang; Jiin-Tsuey Cheng; Chao-Cheng Huang; Rue-Tsuan Liu
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

5.  Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.

Authors:  Changxue Lu; Li Zhao; Hao Ying; Mark C Willingham; Sheue-Yann Cheng
Journal:  Endocrinology       Date:  2010-02-04       Impact factor: 4.736

6.  Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours.

Authors:  S-Y Sheu; F Grabellus; S Schwertheim; K Worm; M Broecker-Preuss; K W Schmid
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

Review 7.  Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas.

Authors:  Pierlorenzo Pallante; Rosa Visone; Carlo Maria Croce; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

Review 8.  Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications.

Authors:  M P Menon; A Khan
Journal:  J Clin Pathol       Date:  2009-07-21       Impact factor: 3.411

9.  Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer.

Authors:  Sylwia E Wojcik; Simona Rossi; Masayoshi Shimizu; Milena S Nicoloso; Amelia Cimmino; Hansjuerg Alder; Vlad Herlea; Laura Z Rassenti; Kanti R Rai; Thomas J Kipps; Michael J Keating; Carlo M Croce; George A Calin
Journal:  Carcinogenesis       Date:  2009-11-19       Impact factor: 4.944

Review 10.  MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype.

Authors:  Libero Santarpia; Milena Nicoloso; George A Calin
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more
  55 in total

1.  Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.

Authors:  Sandya Liyanarachchi; Anna Wojcicka; Wei Li; Malgorzata Czetwertynska; Elzbieta Stachlewska; Rebecca Nagy; Kevin Hoag; Bernard Wen; Rafal Ploski; Matthew D Ringel; Izabella Kozłowicz-Gudzinska; Wojciech Gierlikowski; Krystian Jazdzewski; Huiling He; Albert de la Chapelle
Journal:  Thyroid       Date:  2013-08-29       Impact factor: 6.568

Review 2.  Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Authors:  Mingzhao Xing
Journal:  Endocrinol Metab Clin North Am       Date:  2019-03       Impact factor: 4.741

3.  miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.

Authors:  Rui Li; Jia Liu; Qun Li; Guang Chen; Xiaofang Yu
Journal:  Tumour Biol       Date:  2015-10-19

4.  microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.

Authors:  Aparna Lakshmanan; Anna Wojcicka; Marta Kotlarek; Xiaoli Zhang; Krystian Jazdzewski; Sissy M Jhiang
Journal:  Endocr Relat Cancer       Date:  2014-11-17       Impact factor: 5.678

5.  MicroRNA-338-3p inhibits thyroid cancer progression through targeting AKT3.

Authors:  Guo-Qing Sui; Dan Fei; Feng Guo; Xi Zhen; Qiang Luo; Shuai Yin; Hui Wang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

6.  Expression and clinicopathological role of miR146a in thyroid follicular carcinoma.

Authors:  Elisa Pignatti; Eleonora Vighi; Elisa Magnani; Elda Kara; Luca Roncati; Antonino Maiorana; Daniele Santi; Bruno Madeo; Katia Cioni; Cesare Carani; Vincenzo Rochira; Manuela Simoni; Giulia Brigante
Journal:  Endocrine       Date:  2019-01-30       Impact factor: 3.633

7.  Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2.

Authors:  Hongyu Guan; Weiwei Liang; Zhiwei Xie; Hai Li; Juan Liu; Liehua Liu; Lingling Xiu; Yanbing Li
Journal:  Endocrine       Date:  2014-06-27       Impact factor: 3.633

8.  MicroRNA-196a2 Biomarker and Targetome Network Analysis in Solid Tumors.

Authors:  Eman A Toraih; Manal S Fawzy; Eman A Mohammed; Mohammad H Hussein; Mohamad M El-Labban
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

9.  MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer.

Authors:  Yan-Ran Wu; Hai-Jun Qi; Dan-Fang Deng; Ying-Ying Luo; Sheng-Lan Yang
Journal:  Tumour Biol       Date:  2016-05-17

10.  microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2.

Authors:  Su Dong; Xianying Meng; Shuai Xue; Zewen Yan; Peiyou Ren; Jia Liu
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.